Compassionate rare disease support, built around every patient

Innomar Strategies provides customized support for patients, caregivers, providers, and manufacturer partners navigating rare and ultra rare disease therapies in Canada, combining deep expertise, integrated services, and a compassionate approach tailored to each unique journey.
Female patient sitting in a waiting area and looking out the window.

Navigating rare disease treatment in Canada

 

Rare disease treatment journeys can be complex, highly individualized, and challenging to navigate. Patients and caregivers often face long paths to diagnosis, complex clinical requirements, and reimbursement barriers that can delay access to therapy.

Innomar helps simplify that journey by supporting pharmaceutical manufacturers in the launch and management of rare disease patient support programs in Canada, bringing the expertise, flexibility, and empathy patients need as they navigate the rare disease landscape.

Customized support for every rare disease journey

When it comes to rare diseases, no two journeys are alike. That is why our approach is built around customized support that reflects each individual’s clinical, reimbursement, and personal needs. Our dedicated rare disease teams help to simplify the treatment journey by coordinating reimbursement navigation, nursing and clinic services, and pharmacy support, so patients feel supported and confident navigating every step.
Over 50
rare and ultra-rare disease molecules supported.
More than
25 years
of patient support program experience.
Supporting a child with a rare disease to get access to specialists, to a diagnosis, and to treatment is a long-term, frustrating, and emotional journey.  Watching your child decline due to a lack of access is heart-breaking. As a parent, I am so thankful to any bit of support or attention that we can get because we generally have to navigate and advocate alone.

Caregiver

A young child smiling.

Deep rare disease expertise, backed by proven experience

A young child smiling.

Innomar brings 25 years of patient support program experience and currently supports over 50 rare and ultra-rare disease molecules. Our dedicated rare disease teams of nurses and reimbursement specialists understand the realities of the Canadian rare disease landscape and the importance of designing programs that are both agile and patient-centric.

We combine experienced and compassionate associates, strong reimbursement knowledge, and long-standing relationships across the rare disease community to help customers launch and evolve programs with confidence.

A young child smiling.
A row of Canada flags with a bridge in the background.

Partnership that strengthens access from launch onward

A row of Canada flags with a bridge in the background.
Launching a rare disease patient support program in Canada requires more than operational readiness – it requires a partner who understands the market, aligns to your business strategy, and can help anticipate challenges to remove barriers for patients.

Innomar brings established relationships with key stakeholders and advocates to help inform patient support program design before launch. We also take a proactive approach to reimbursement strategy, market access initiatives, and data planning, including real-world evidence to help ensure programs support both patient needs and manufacturer goals.


For manufacturers that are new to Canada or launching their first rare disease therapy, choosing the right partner is critical. Innomar acts as an extension of your team, bringing local market knowledge, operational experience, and a collaborative model designed to help you move forward with greater clarity.

Our goal is to help you establish and operationalize a rare disease patient support program that is personalized, scalable, and aligned to the needs of your product, your patients, and your long-term strategy across the product life cycle.

A row of Canada flags with a bridge in the background.

What sets us apart

Rare disease expertise that runs deep

Our dedicated rare disease teams bring specialized knowledge, continuous training, compassion and experience supporting more than 50 rare and ultra-rare disease molecules in Canada. Through our Rare Disease Community of Practice, multidisciplinary experts across Innomar collaborate to share best practices, discuss emerging trends, and continuously strengthen the specialized knowledge that supports rare disease patients and their care teams.

Customized, high-touch design

We configure the PSP services to align with the needs of the product and the patient, helping to create a more compassionate and coordinated experience for patients, caregivers, and healthcare professionals along the product lifecycle.


Strong community and stakeholder relationships

We maintain ongoing leadership and partnership with the Canadian Organization for Rare Disorders (CORD), while building trusted relationships with healthcare professionals, key opinion leaders, payers, and patient advocacy groups.

Reimbursement navigation with escalation support

Our experienced reimbursement associates understand changing payer requirements and can escalate complex cases to our complex reimbursement team when needed.

Integrated and flexible service delivery

Our flexible support model brings together a wide range of integrated services, including patient support programs, nursing services, pharmacy coordination, and data strategy, to provide value to stakeholders across the treatment journey.

Support for market access and outcomes strategy

We take a proactive approach to data strategy, real-world evidence and health economics and outcomes research integration to help support market access initiatives and real-world outcomes.

Real world evidence: The importance for rare disease therapies

Making decisions about rare disease therapies requires robust data, but that data can be hard to come by. Randomized clinical trials, a rich source of data, aren’t always feasible due to the smaller size of these populations. Hear from Belinda Yap, Director, Health Economics & Outcomes Research (HEOR), about ways you can use real world evidence (RWE) to bridge this data gap from pre- to post-launch.

Care beyond expectations

For people living with rare diseases and their caregivers, every interaction matters. Innomar helps deliver a more personalized, connected, and compassionate experience across the treatment journey.

Discover a more integrated and collaborative approach to your rare disease strategy in Canada.

Young child visiting a doctor.